Laura Andrade

Laura Andrade is an accomplished director in pharmaceutical CMC at GH Research plc, with a career spanning over two decades in respiratory product development. Previous roles include R&D and Innovation Associate Director at Insud Pharma and R&D Associate Director at Chemo, where significant achievements included the development of Braltus, the first generic SPIRIVA in Europe and Australia, and the unique DPI product approved with in vitro-only data for Formoterol. Laura's expertise is complemented by a robust educational background, including a Corporate Development Program from IESE Business School and a degree in Pharmacy from Universidad de Alcalá. Additionally, Laura has experience in health inspection and has honed leadership skills through specialized training.